New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera's Ability to Risk Stratify and Detect Progression Early
Le Lézard,
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in…